Professor Herder, in your resignation letter, you state that the minister's request was no different in form and substance from industry talking points.
Industry talking points go beyond just wanting to suspend consultations. When I read the letter, what I see is a federal minister of Health who is concerned about the views of his provincial counterparts, who questions the impact of federal reform on potential drug shortages and who wants to ensure that the serious concerns raised by some stakeholders are unfounded. There is a lot of talk about the industry, but that also includes many patient groups.
How is that similar to what the industry is saying, and how does that undermine the credibility of the board?